Dietary supplementation of resveratrol suppresses colonic tumour incidence in 1,2-dimethylhydrazine-treated rats by modulating biotransforming enzymes and aberrant crypt foci development - PubMed (original) (raw)

Dietary supplementation of resveratrol suppresses colonic tumour incidence in 1,2-dimethylhydrazine-treated rats by modulating biotransforming enzymes and aberrant crypt foci development

Murugan Sengottuvelan et al. Br J Nutr. 2006 Jul.

Abstract

Diet-induced changes in the activities of bacterial enzymes are known to play a role in colon cancer development. Resveratrol has been implicated as a protective agent in carcinogenesis. In the present study, the effect of resveratrol on the activities of faecal and colonic biotransforming enzymes such as beta-glucuronidase, beta-glucosidase, beta-galactosidase, mucinase, nitroreductase and faecal sulfatase activity was assessed. The total number of aberrant crypt foci and their distribution in the proximal, medial and distal colon were observed in 1,2-dimethylhydrazine (DMH)-induced rats (group 3) and other treatment groups (groups 4-6). DMH (0.02 g/kg body weight) was given subcutaneously once a week for 15 consecutive weeks, and the experiment was terminated at 30 weeks. DMH-treated rats showed elevated levels of cancer-associated bacterial enzyme activities, whereas on resveratrol supplementation in three different regimens, rats showed lowered activities. Resveratrol supplementation throughout the experimental period (group 6) exerted a more pronounced effect (P < 0.01) by modulating the development of aberrant crypt foci and the activities of bacterial enzymes than did the other treatment regimens (groups 4 and 5). Thus, the present results demonstrate the inhibitory effect of resveratrol on DMH-induced colon carcinogenesis in rats.

PubMed Disclaimer

Cited by

Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer.
Nguyen AV, Martinez M, Stamos MJ, Moyer MP, Planutis K, Hope C, Holcombe RF. Nguyen AV, et al. Cancer Manag Res. 2009 Apr 3;1:25-37. Cancer Manag Res. 2009. PMID: 21188121 Free PMC article.
Resveratrol and its Related Polyphenols Contribute to the Maintenance of Genome Stability.
Matsuno Y, Atsumi Y, Alauddin M, Rana MM, Fujimori H, Hyodo M, Shimizu A, Ikuta T, Tani H, Torigoe H, Nakatsu Y, Tsuzuki T, Komai M, Shirakawa H, Yoshioka KI. Matsuno Y, et al. Sci Rep. 2020 Mar 25;10(1):5388. doi: 10.1038/s41598-020-62292-5. Sci Rep. 2020. PMID: 32214146 Free PMC article.
High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition.
Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stødkilde-Jørgensen H, Møller N, Jessen N, Pedersen SB, Jørgensen JO. Poulsen MM, et al. Diabetes. 2013 Apr;62(4):1186-95. doi: 10.2337/db12-0975. Epub 2012 Nov 28. Diabetes. 2013. PMID: 23193181 Free PMC article. Clinical Trial.
The Role of Resveratrol in Cancer Therapy.
Ko JH, Sethi G, Um JY, Shanmugam MK, Arfuso F, Kumar AP, Bishayee A, Ahn KS. Ko JH, et al. Int J Mol Sci. 2017 Dec 1;18(12):2589. doi: 10.3390/ijms18122589. Int J Mol Sci. 2017. PMID: 29194365 Free PMC article. Review.
Curcumin synergizes with resveratrol to inhibit colon cancer.
Majumdar AP, Banerjee S, Nautiyal J, Patel BB, Patel V, Du J, Yu Y, Elliott AA, Levi E, Sarkar FH. Majumdar AP, et al. Nutr Cancer. 2009;61(4):544-53. doi: 10.1080/01635580902752262. Nutr Cancer. 2009. PMID: 19838927 Free PMC article.

Dietary supplementation of resveratrol suppresses colonic tumour incidence in 1,2-dimethylhydrazine-treated rats by modulating biotransforming enzymes and aberrant crypt foci development - PubMed (original) (raw)